Management of Non-Narcolepsy Hypersomnia and Excessive Daytime Sleepiness
- By Imran H. Iftikhar1
-
View Affiliations Hide AffiliationsAffiliations: 1 Department of Medicine, Division of Pulmonary, Allergy, Critical Care & Sleep Medicine, Emory University School of Medicine and the Atlanta Veterans Affairs Medical Center, Atlanta, GA, USA
- Source: The Latest Trends in Sleep Medicine , pp 1-19
- Publication Date: March 2022
- Language: English
- Previous Chapter
- Table of Contents
- Next Chapter
The International Classification for Sleep Disorders- third edition (ICSD-3) has classified central disorders of hypersomnolence as, Narcolepsy type 1 and type 2, idiopathic hypersomnia (IH), KleineLevin syndrome (KLS), hypersomnia due to a medical or neurologic disorder, hypersomnia due to medication or substance, hypersomnia associated with psychiatric disorders, and insufficient sleep syndrome. A number of pharmacological treatment options are now available for Narcolepsy type 1 and type 2. However, for conditions like IH and KLS, much work is still being done to understand the underlying pathophysiologic mechanisms and consequently, these conditions have the least amount of high-grade evidence on pharmacologic options, and most medicines are used off-label. This chapter focuses on treating non narcoleptic hypersomnia syndromes- those commonly encountered in Sleep disorders clinics such as residual hypersomnia despite having a patient adherent to therapeutic positive airway pressure settings, to some uncommon conditions like IH and an exceedingly rare condition like KLS. New medications like solriamfetol and pitolisant and their possible use in some of these conditions is also discussed in this chapter
-
From This Site
/content/books/9789815051032.chap1dcterms_subject,pub_keyword-contentType:Journal105